Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4571 - Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study)

Date

09 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Hepatobiliary Cancers

Presenters

Julien Edeline

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

J. Edeline1, Y. Touchefeu2, B. Guiu3, O. Farges4, D. Tougeron5, P. Compagnon6, L. Chone7, B. Campillo-Gimenez8, M. Pracht1, A. Lievre9, S. Le Sourd1, K. Boudjema10, E. Garin11, E. Boucher1

Author affiliations

  • 1 Medical Oncology, Centre Eugene Marquis, 35042 - Rennes/FR
  • 2 Imad, Department Of Gastroenterology, Nantes University Hospital, 44093 - Nantes/FR
  • 3 Interventional Radiology, CHU Montpellier, Montpellier/FR
  • 4 Hepatobiliary Surgery, AP-HP Hôpital Beaujon, Clichy/FR
  • 5 Department Of Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 6 Hepatobiliary Surgery And Transplantation, CHU Henri Mondor, 94000 - Creteil/FR
  • 7 Hepatology, CHU Nancy, Nancy/FR
  • 8 Clinical Research, Centre Eugene Marquis, 35042 - Rennes/FR
  • 9 Gastroenterology, CHU Pontchaillou, 35042 - Rennes/FR
  • 10 Hepatobiliary Surgery, CHU Pontchaillou, Rennes/FR
  • 11 Nuclear Medicine, Centre Eugene Marquis, 35042 - Rennes/FR
More

Resources

Abstract 4571

Background

Patients with non-resectable intra-hepatic cholangiocarcinoma (ICC) have a bad prognosis, and the efficacy of chemotherapy is limited. SIRT is a promising treatment option in hepatic tumors. In ICC there is no prospective studies of combination SIRT with chemotherapy.

Methods

This phase II single-arm study prospectively included patients with non-resectable ICC (liver-only or limited extra-hepatic disease) in 7 centers. Patients received Cisplatin 25mg/m2 and Gemcitabine 1000mg/m2 (reduced to 300mg/m2 the cycles just before and following SIRT) day 1 and 8 of a 21-days cycles. SIRT was delivered during cycle 1 (unilobar disease), or cycles 1 and 3 (bilobar disease). Primary objective was response rate (RR) at 3 months according to RECIST 1.1, with the objective to show a RR > 22%. Secondary objectives were toxicity, Progression-Free Survival (PFS), Overall Survival (OS), disease control rate (DCR) and RR according to Choi criteria.

Results

45 patients met clinical inclusion criteria, and 41 were deemed treatable with SIRT after pretreatment angiography and included in the study. 34% of patients had abdominal extrahepatic lesions, 17% had thoracic lesions, tumor was unilobar in 66%, and median CA19.9 was 1499 UI/L. Grade 3 or more hematological toxicities were seen in 27 (66%) patients, and grade 3 or more non-hematological toxicities in 21 (49%). Median number of chemotherapy cycles were 6 (range 1-15). RECIST RR was 39% [90% CI: 26-53], and DCR was 98% (all 40 evaluable patients had disease control). In the 29 patients evaluated with Choi criteria, RR was 86%. 9 patients (22%) were downstaged to surgery, with 8 (20%) achieving R0 resection. Median PFS was 13 months [95% CI: 7-NR], with 12- and 24-months PFS rates of 51% and 37%, respectively. Median OS was 21 months [95% CI: 14-NR], with 12- and 24-months OS rates of 73% and 36%, respectively.

Conclusions

Combination of chemotherapy and SIRT achieved promising activity in first-line treatment of inoperable ICC, with median PFS and OS comparing favorably with chemotherapy-only historical data, and a significant proportion of patients downstaged to surgery. Toxicity was manageable. Further studies of SIRT in ICC are warranted.

Clinical trial identification

NCT01912053

Legal entity responsible for the study

Centre Eugene Marquis, Rennes, France

Funding

BTG

Disclosure

J. Edeline: Consultant for BTG. E. Garin: Consultant for BTG. E. Boucher: Employee with BTG. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.